Determining the Best Estimate of Probability of Passing Multiple Stage Tests: Part 1–Content Uniformity

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-05-02-2021
Volume 45
Issue 5
Pages: 36-43

This article introduces a practical approach to determining the best estimate for probability of passing uniformity of dosage units (content uniformity) using probability vs. lot coverage charts and tables constructed using simulated probability and lot coverage (LC1) data.

xyz+ - Stock.adobe.com

xyz+ - Stock.adobe.com

Peer-Reviewed

Submitted: August 24, 2020
Accepted: October 12, 2020

Abstract

This article introduces a practical approach to determining the best estimate for probability of passing uniformity of dosage units (content uniformity) using probability vs. lot coverage charts and tables constructed using simulated probability and lot coverage (LC1) data. The best estimation concept is to demonstrate that the probability estimates, especially for those approaching 100%, are slightly different (deviated) from the exact calculated values by not more than (NMT) the statistically acceptable deviation limits.

Click here for a PDF of this article

Peer-reviewed research

Submitted: Aug. 24, 2020
Accepted: Oct. 12, 2020

About the author

Pramote Cholayudth is an industrial pharmacist with more than 40 years of experiences. He is a guest speaker on Process Validation to industrial pharmaceutical scientists organized by Thailand’s FDA. He is the founder and manager of PM Consult and can be contacted via cpramote2000@yahoo.com.

Article details

Pharmaceutical Technology
Vol. 45, No. 5
May 2021
Pages: 36-43

Citation

When referring to this article, please cite it as P. Cholayudth, “Determining the Best Estimate of Probability of Passing Multiple Stage Tests: Part 1–Content Uniformity,” Pharmaceutical Technology 45 (5) 2021.

Recent Videos
Drug Digest: Strategic Partnerships
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development